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Abstract Epidermal growth factor receptor (EGFR) is
involved in multiple aspects of cancer cell biology. EGFR
has already been identified as an important target for cancer
therapy, with various kinds of EGFR inhibitors currently
used in treatment of several human cancers. Recently,
EGFR and its downstream signaling pathways were
identified as being associated with cisplatin sensitivity. In
addition, EGFR inhibitors have shown significant promise
for patients who failed cisplatin-based therapy. In this study,
we investigated whether treatment with an EGFR inhibitor
improves cisplatin sensitivity in oral squamous cell carci-
noma (OSCC) cell lines. The effects of a combination of
AG1478, a specific EGFR tyrosine kinase inhibitor, with
cisplatin were evaluated in cultured OSCC cell lines and
cisplatin-resistant sublines. Higher expression of EGFR and
p-EGFR was found in the two cisplatin-resistant cell lines
compared with the corresponding parental cell lines. In
addition, augmented inhibition of OSCC cell growth by the
combination of AG1478 with cisplatin was found in both
cell lines. These results suggest that the combination of an
EGFR inhibitor and cisplatin may be useful as a rational
strategy for the treatment of patients with oral cancer with
acquired cisplatin resistance.
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(p-EGFR) phosphorylated EGFR
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Introduction
Epidermal growth factor receptor (EGFR) is expressed at
high levels in a variety of solid tumors including oral cancers
[1, 2]. EGFR and its downstream signaling pathways are
involved in multiple aspects of cancer cell biology,
including tumor cell proliferation, inhibition of apoptosis,
invasion, metastasis, and angiogenesis [1–4]. EGFR has
already been identified as an important target for cancer
therapy, and various kinds of EGFR inhibitors are currently
used in the treatment of several human cancers [5–10].
Cisplatin-based combination chemotherapy displays sig-
nificant anti-tumor activity against solid tumors of oral
squamous cell carcinoma (OSCC). However, the effective-
ness of cisplatin in the treatment of recurrent/metastatic
tumors is limited because of acquired or intrinsic resistance.
EGFR and its signaling pathways are involved in the
mechanism of cisplatin resistance. Cells that are resistant to
cisplatin have an altered response to the EGF ligand and
enhanced activation of the protein kinase [11]. In addition,
several studies have suggested that enhanced expression of
EGFR may be associated with cisplatin resistance in a
variety of solid tumors including oral cancers [12, 13].
Increased EGFR expression may be a survival response by
some tumors exposed to chemotherapeutic agents [14].
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resistant cells has also been reported previously [13]. EGFR
inhibitors have shown significant activity in cases failing
cisplatin-based therapy [15, 16]. Therefore, EGFR blockade
may be a useful therapeutic tool in the treatment of patients
with acquired cisplatin resistance.
In this study, we established a cisplatin-resistant cell line
from an OCSS-derived cell line and investigated the
differential EGFR and phosphorylated EGFR (p-EGFR)
expression between OSCC cell lines and the cisplatin-
resistant sublines. In addition, we examined the effect of
combination therapy with an EGFR inhibitor and cisplatin
on the growth of OSCC cells.
Materials and Methods
Cell Lines
Two human OSCC cell lines have been established at
Wakayama Medical University, Wakayama, Japan. The H-1
line was derived from a biopsy specimen of moderately
differentiated OSCC in the lower gingiva. The Sa-3 line
was derived from a biopsy specimen of well-differentiated
OSCC in the upper gingiva. Both cell lines were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Nissui,
Tokyo, Japan) supplemented with 10% fetal bovine serum
(FBS; Equitech-Bio, Kerrville, TX, USA), 100 units/ml
penicillin, and 100 μg/ml streptomycin (Gibco BRL, Grand
Island, NY, USA) in a highly humidified atmosphere of 5%
CO2 at 37°C.
In accordance with previously described methods [17,
18], the cisplatin (CDDP)-resistant sublines H-1/CDDP and
Sa-3/CDDP were established by repeated subculture in the
presence of increasing concentrations of cisplatin (Nippon
Kayaku Corporation, Tokyo, Japan), from 0.1 μg/ml until
cells became fully resistant to cisplatin and could grow
exponentially; in each case the final cisplatin concentration
was 0.5 μg/ml. The drug-resistant cell lines were passed in
drug-free medium, and there was no loss of resistance
during the two-month testing period.
Cell Growth Analysis with MTT Assay
Cells were seeded in 96-well plates at 2000 cells per well in
DMEM containing 10% FBS. After 24 h, cells were
exposed to one of nine concentrations (0.05, 0.1, 0.25,
0.5, 1, 1.25, 2.5, 5 and 10 μg/ml) of cisplatin or five
concentrations (1, 5, 10, 20 and 30 μM) of AG1478
(Calbiochem San Diego CA, USA). After cells were
incubated with cisplatin or AG1478 for 24 h, medium
was changed to drug-free DMEM and cells were incubated
for an additional 72 h. Thereafter, the number of cells per
well was quantified with a MTT cell growth assay kit
(Funakoshi, Tokyo, Japan) according to the manufacturer’s
instructions. Briefly, after 10 μl MTT solution was added to
each well, the well was incubated for 4 h and scanned at
550–630 nm by a MTP-300 microplate reader (Corona,
Tokyo, Japan). Six wells were used for each drug
concentration, and the experiment was repeated three times.
The 50% inhibitory concentration (IC50) was calculated
from the survival curve. In another experiment, to test
whether the combination of cisplatin and AG1478 would
achieve higher growth inhibition than the single agent at a
concentration lower than the IC50, fixed concentrations of
each drug were then tested in combination treatment of
OSCC cell lines. All cells were exposed to AG1478 for 1 h
before cisplatin. The statistical significance of differences
was analyzed by applying Mann–Whitney U-test. The level
of significance was set at p<0.05.
Western Blot Analysis
Subconfluent cells were scraped from culture dishes, washed
twice with phosphate buffered saline (PBS), and suspended
in 700 μl Western blot lysis buffer containing 62.5 mM Tris–
HCl (ph 6.8), 25% glycerol, and 2% sodium dodecyl sulfate
(SDS).Sampleswerecentrifugedat15,000rpm for20minat
4°C, after which supernatants were collected. After heating
at 95°C for 5 min, equal amounts of proteins were separated
with the use of 10% SDS-PAGE. After electrophoresis,
proteins were transferred to a PVDF membrane in Tris-
glycinebuffercontaining20%methanol. Themembrane was
blocked with 3% skim milk containing 0.01% polyoxyeth-
lene sorbitan monolaurate for 60 min, and incubated
overnight with the corresponding primary antibodies {a
1:750 dilution of anti-rabbit polyclonal EGFR antibody
[Santa Cruz Biotechnology, Santa Cruz, CA, USA], and a
1:750 dilution of anti-goat polyclonal p-EGFR (Tyr 1173)
antibody [Santa Cruz Biotechnology]} at 4°C. The mem-
brane was washed three times for 5 min each with PBS
containing 0.05% polyoxyethlene sorbitan monolaurate and
horseradish peroxidase-conjugated anti-rabbit or anti-goat
antibody for 1 h at room temperature, respectively. Protein
signals were visualized by enhanced chemiluminescence
using ECL Western blotting detection reagents (Amersham,
Arlington Heights, IL, USA) for 1 min and exposed to
Kodak Biomax XAR film.
Results
Single Agent Effects
The sensitivities of all cell lines to various concentrations of
cisplatin and AG1478 were determined by MTT assay and
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cisplatin and AG1478 are shown in Table 1. The IC50
values of the H-1/CDDP and Sa-3/CDDP lines to cisplatin
were about 10-fold greater than the values for the parental
H-1 and Sa-3 lines. Resistance of all cell lines to AG1478
was similar, but the IC50 values for parental cell lines
tended to be slightly higher.
Combination Effects
All cell lines were treated with AG1478 (10 μM) for 1 hour
before cisplatin (0.25 μg/ml) for 24 h. The combination of
AG1478 with cisplatin inhibited cell growth >60% in
parental cell lines > 50% in cisplatin-resistant cell lines
(Fig. 2). In both cell lines, we showed augmented effects of
inhibition and showed a large effect of augmentation in
cisplatin-resistant cell lines.
Expression of EGFR and p-EGFR
To investigate the molecular basis for the increased
sensitivity of chemoresistant tumors to cisplatin, we used
Western blot analysis to determine the level of EGFR and
p-EGFR expression in parental and cisplatin-resistant cell
lines. Higher EGFR and p-EGFR expression was found in
cisplatin-resistant cell lines compared with the correspond-
ing parental cell lines (Fig. 3).
Discussion
Our studies suggest that changes in the expression of EGFR
play an important role in regulating the drug-resistant
Fig. 1 Inhibitory effects of cisplatin and AG1478 on growth of OSCC
cell lines. The four lines, H-1, H-1/CDDP, Sa-3, and Sa-3/CDDP, were
treated with cisplatin (0.05–10 μg/ml; a) or AG1478 (1–30 μM; b) for
24 h as described in the Materials and methods section. Cell viability
was measured by MTT assay and is expressed as a percentage relative
to control cells. The results showed that cisplatin and AG1478
inhibited OSCC cell growth in a dose-dependent manner
Table 1 Cisplatin and AG1478 sensitivity of OSCC cell lines
Cell line IC50 IC50
Cisplatin (μg/ml) AG1478 (μM)
H-1 0.49 25.3
Sa-3 0.43 28.5
H-1/CDDP 6.5 23.3
Sa-3/CDDP 5.9 21.2
Fig. 2 Effect of a combination of AG1478 with cisplatin on growth of
OSCC cell lines. The four lines, H-1, H-1/CDDP, Sa-3, and Sa-3/
CDDP, were treated with AG1478 (10 μM) for 1 h before addition of
cisplatin (0.25 μg/ml) for 24 h. Cell viability was measured by MTT
assay and is expressed as a percentage relative to control cells. In both
cell lines, we showed augmented effects of inhibition and showed
large-effect augmentation in cisplatin-resistant cell lines. *p<0.05,
compared with cisplatin-treated cells
Fig. 3 Total expression of epidermal growth factor receptor (EGFR)
and phosphorylated receptor (p-EGFR). Total expression of EGFR
and p-EGFR was determined by Western blot analysis. Ten micro-
grams of total cellular lysates prepared from parental and cisplatin
(CDDP)-resistant cells were resolved by electrophoresis, transferred to
a PVDF membrane, and blotted with anti-EGFR and anti-p-EGFR
antibodies as described in the Materials and methods section
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widely used for chemotherapy of many malignancies,
especially of oral squamous cell carcinoma (OSCC).
However, the effectiveness of cisplatin in the treatment of
recurrent/metastatic tumors is limited because of acquired
or intrinsic resistance. Increased EGFR expression may be a
survival response by some tumors exposed to chemother-
apeutic agents [14]. In our study, higher EGFR expression
was found in two cisplatin-resistant cell lines compared
with the corresponding parental cell lines (Fig. 3).
EGF receptors initiate cytoplasmic signaling through
autophosphorylation of their intracellular domains [19].
Phosphorylated EGFR (p-EGFR) cytoplasmic tyrosine
residues initiate the activated protein kinase pathway [20].
This mitogen-activated protein kinase (MAPK) pathway is
involved in the mechanism of cisplatin resistance [21–23].
Activation of JNK and p38 by cisplatin has been shown to
promote apoptotic cell death [22, 23]. In addition, activa-
tion of the ERK pathway by cisplatin was reported to
promote induction of cell death [21]. In our study, higher p-
EGFR expression was found in two cisplatin-resistant cell
lines compared with the corresponding parental cell lines.
These findings offer further evidence that activation of
EGFR downstream signaling pathways is involved in
cisplatin sensitivity.
The effect of combining EGFR inhibitors with cytotoxic
agents has been studied in various types of cancer [16, 24].
The quinazoline derivative AG1478 is a specific reversible
inhibitor of EGFR. The cancer cell growth depression effect
of AG1478 has been reported in various carcinomas [24–
26]. In our study, the combination of AG1478 and cisplatin
showed augmented effects of inhibition in both cell lines
and showed large-effect augmentation in cisplatin-resistant
cell lines. These results suggest that acquired resistance to
cisplatin is associated with enhanced sensitivity to an
EGFR tyrosine kinase inhibitor, which correlates with
increased EGFR and p-EGFR expression.
Augmented effects of inhibition of OSCC cell growth
through the combination of AG1478 and cisplatin provide a
potential and novel strategy for patients with oral cancer
with acquired cisplatin resistance. In addition, it would be
very advantageous if an equal chemotherapeutic effect
could be obtained with a smaller dosage of cisplatin. The
combination of AG1478 and cisplatin against OSCC
definitely deserves additional in vivo and clinical studies.
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